抗EGFR治疗在头颈部鳞癌中的研究进展

doi:10.11904/j.issn.1002-3070.2023.03.014

Abstract

Abstract: Epidermal growth factor receptor(EGFR)plays an important role in the occurrence and development of head and neck squamous cell carcinoma(HNSCC).EGFR,as a biomarker,participates in multiple signaling pathways and is highly expressed in HNSCC.At present,a series of anti-EGFR targeted therapy drugs have been used in clinical research and treatment of HNSCC,including cetuximab,nituzumab,afatinib,etc.This article provides a review of the current treatment status and research progress of HNSCC anti-EGFR,in order to provide a reference for drug selection and prognosis.

Key words: Squamous cell carcinoma of the head and neck, Epidermal growth factor receptor, Targeted therapy, Security

CLC Number:

R733.1

LUN Lixin, ZHONG Zhenbin, ZHAO Xinyu, WU Chou, HAO Chuncheng. Research progress of anti-EGFR therapy in head and neck squamous cell carcinoma[J]. Journal of Practical Oncology, 2023, 37(3): 276-280.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.03.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I3/276

References

1 Gao L,Zhang A,Yang F,et al.Immunotherapeutic strategies for head and neck squamous cell carcinoma(HNSCC):current perspectives and future prospects[J].Vaccines,2022,10(8):1272.
2 Verma J,Dhingra V,Srivastava S,et al.Evaluation of epidermal growth factor receptor expression by a new scoring system in head-and-neck squamous cell carcinoma and its association with various pathological prognostic factors[J].J Oral Maxillofac Pathol,2018,22(1):11-17.
3 Cramer JD,Burtness B,Le QT,et al.The changing therapeutic landscape of head and neck cancer[J].Nat Rev Clin Oncol,2019,16(11):669-683.
4 Xu X,Li R,Zhang L,et al.Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma[J].Diagn Pathol,2021,16(1):110.
5 Nair S,Bonner JA,Bredel M.EGFR mutations in head and neck squamous cell carcinoma[J].Int J Mol Sci,2022,23(7):3818.
6 Patel B,Saba NF.Current aspects and future considerations of EGFR inhibition in locally advanced and recurrent metastatic squamous cell carcinoma of the head and neck[J].Cancers,2021,13(14):3545.
7 Yang Z,Liao J,Schumaker L,et al.Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma[J].Oral Oncol,2022,131:105939.
8 Peng X,Zhou Y,Tao Y,et al.Nasopharyngeal carcinoma:the role of the EGFR in epstein-barr virus infection[J].Pathogens,2021,10(9):1113.
9 Caldieri G,Malabarba MG,Di FP,et al.EGFR trafficking in physiology and cancer[J].Prog Mol Subcell Biol,2018,57:235-272.
10 Byeon HK,Ku M,Yang J.Beyond EGFR inhibition:multilateral combat strategies to stop the progression of head and neck cancer[J].Exp Mol Med,2019,51(1):1-14.
11 Ang KK,Berkey BA,Tu X,et al.Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J].Cancer Res,2002,62(24):7350-7356.
12 Fasano M,Della Corte CM,Viscardi G,et al.Head and neck cancer:the role of anti-EGFR agents in the era of immunotherapy[J].Ther Adv Med Oncol,2021,13:1758835920949418.
13 Zaryouh H,De PI,Baysal H,et al.Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma[J].Med Res Rev,2022,42(1):112-155.
14 Kumar P,Mangla B,Javed S,et al.Gefitinib:An updated review of its role in the cancer management,its nanotechnological interventions,recent patents and clinical trials[J].Recent Pat Anticancer Drug Discov,2023,18(4):448-469.
15 Patil VM,Noronha V,Joshi A,et al.A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer[J].Cancer,2019,125(18):3184-3197.
16 Martins RG,Parvathaneni U,Bauman JE,et al.Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck:a randomized phase II trial[J].J Clin Oncol,2013,31(11):1415-1421.
17 Burtness B,Haddad R,Dinis J,et al.Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck:a randomized clinical trial[J].JAMA Oncol,2019,5(8):1170-1180.
18 Tang X,He J,Li B,et al.Efficacy and safety of gefitinib in patients with advanced head and neck squamous cell carcinoma:a meta-analysis of randomized controlled trials[J].J Oncol,2019,5:6273438.
19 Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J].N Engl J Med,2006,354(6):567-578.
20 She L,Tian K,Han J,et al.Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma:an updated KEYNOTE-048 based cost-effectiveness analysis[J].Oral Oncol,2022,129:105871.
21 Seiwert TY,Fayette J,Cupissol D,et al.A randomized,phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck[J].Ann Oncol,2014,25(9):1813-1820.
22 Hecht M,Hahn D,Wolber P,et al.A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer[J].Cancers,2021,13(14):3413.
23 Huang TL,Chuang HC,Tsai MH,et al.Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer[J].Biomed J,2021,45(5):838-846.
24 Sano D,Fujisawa T,Tokuhisa M,et al.Real-world treatment outcomes of the EXTREME regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck:a multi-center retrospective cohort study in Japan[J].Anticancer Res,2019,39(12):6819-6827.
25 Surmeli ZG,Ozveren A,Arslan C,et al.Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma[J].Indian J Cancer,2019,56(1):4-8.
26 Buchbinder EI,Desai A.CTLA-4 and PD-1 pathways similarities,differences,and implications of their inhibition[J].Am J Clin Oncol,2016,39(1):98-106.
27 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicenter,phase 1b trial[J].Lancet Oncol,2016,17(7):956-965.
28 Ferris RL,Blumenschein G,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].New Engl J Med,2016,375(19):1856-1867.
29 Sacco AG,Chen R,Worden FP,et al.Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma:an open-label,multi-arm,non-randomised,multicentre,phase 2 trial[J].Lancet Oncol,2021,22(6):883-892.

[1]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[2]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[3]	ZHAO Yaru, WU Yun. Research status of common biomarkers and corresponding targeted therapy for gastric cancer [J]. Journal of Practical Oncology, 2022, 36(5): 483-488.
[4]	ZHENG Yanli, HE Jianxia. Research progress of DNA methylation in diffuse large B-cell lymphoma [J]. Journal of Practical Oncology, 2022, 36(3): 259-262.
[5]	CHEN Su, SUI Hong. Research progress of anti-HER2 therapy in metastatic colorectal cancer [J]. Journal of Practical Oncology, 2022, 36(3): 288-292.
[6]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[7]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[8]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.
[9]	YANG Siqi,SONG Qibin,LI Qingqing,YAO Yi. Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 73-77.
[10]	SONG Jiayu, FENG Yue, WANG Zhao, ZHANG Yunyan. The latest research progress of the correlation between exosomes and gynecological malignant tumor [J]. Journal of Practical Oncology, 2020, 34(6): 571-575.
[11]	FAN Xiaona,WANG Dan,LI Qingwei,LI Zhiwei. Advances in research on adjuvant drug threapy for postoperative pancreatic cancer [J]. Journal of Practical Oncology, 2020, 34(3): 249-253.
[12]	LI Guozheng, PANG Da. Progression in the treatment of HER2-positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(1): 74-78.
[13]	ZUO Zhibo, GUO Zhiqin, WANG Zhen, YANG Hongjie, WU Wanxin. Research progress of Semaphorin 3F in tumors [J]. Journal of Practical Oncology, 2020, 34(1): 88-92.
[14]	ZHAN Qi, ZHOU Sheng, LOU Liping. The expression and prognostic value of EGFR,HER2 and HER3 in cholangiocarcinoma [J]. Journal of Practical Oncology, 2019, 33(6): 491-496.
[15]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.

Research progress of anti-EGFR therapy in head and neck squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments